Paper33558705
USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription.
Jie X and 11 others. Cell Death Differ, 2021. Cited by 82 papers, by iCite.
Cite this record
ConductScience Library. USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription. Papers, record 33558705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33558705
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Jumonji Domain-Containing Histone Demethylases | Major topic |
| Lung Neoplasms | Major topic |
| Radiation Tolerance | Major topic |
| Transforming Growth Factor beta2 | Major topic |
| Ubiquitin Thiolesterase | Major topic |
| Ubiquitination | Major topic |
| Animals | |
| Carcinogenesis | |
| Cell Line, Tumor | |
| Cell Transformation, Neoplastic | |
| Humans | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Signal Transduction | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 81874041 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 81874218 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 2019CFA063 | Natural Science Foundation of Hubei Province (Hubei Provincial Natural Science Foundation) | PubMed |
Source PubMed
References2
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10987278 | Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. | Cancer Res | 2000 | https://conductscience.org/library/papers/10987278 | PubMed |
| 2 | 31285948 | Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE2 signaling. | Am J Cancer Res | 2019 | https://conductscience.org/library/papers/31285948 | PubMed |
Cited by61
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 82 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42852008 | Geno-guided targeting of ferroptosis: a multi-layered network to overcome radioresistance in lung cancer. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42852008 | PubMed |
| 42794600 | Peripheral Blood Transcriptomic Profile Associated with Cutaneous Radiation Injury in Cancer Patients Undergoing Radiotherapy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794600 | PubMed |
| 42724680 | Pathological role of deubiquitinating enzymes in lung cancer: recent insights and advances. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42724680 | PubMed |
| 42582931 | Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42582931 | PubMed |
| 42343427 | Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42343427 | PubMed |
| 42315669 | USP9X regulates copper-induced CASP9/CASP3/GSDME-dependent pyroptosis by deubiquitinating JAK1. | Apoptosis | 2026 | https://conductscience.org/library/papers/42315669 | PubMed |
| 41946992 | Global analysis of cancer cell responses to USP9X inhibition. | EMBO J | 2026 | https://conductscience.org/library/papers/41946992 | PubMed |
| 41885448 | PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/41885448 | PubMed |
| 41661469 | Mechanism of FOXP2 in the Hepatocellular Carcinoma Progression via Ferroptosis Through RBM15B-Mediated m6A Modification. | Appl Biochem Biotechnol | 2026 | https://conductscience.org/library/papers/41661469 | PubMed |
| 41635813 | Spotlights on ubiquitin-specific proteases in lung cancer: from multifaceted pathophysiological mechanisms to potential therapeutic targets. | PeerJ | 2026 | https://conductscience.org/library/papers/41635813 | PubMed |
| 41614901 | Role of the Super-Enhancer Component Bromodomain Protein 4 in the Radiation Response of Human Head and Neck Squamous Cell Carcinoma Cells. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/41614901 | PubMed |
| 41522168 | Bibliometrics and potential gene analysis of post-translational modifications in lung cancer. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/41522168 | PubMed |
| 41490602 | The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/41490602 | PubMed |
| 41488674 | PSMD14 drives lung adenocarcinoma progression through HMMR stabilization and dual activation of TGF-β/Smad and PI3K/AKT/mTOR signaling. | Front Immunol | 2025 | https://conductscience.org/library/papers/41488674 | PubMed |
| 41477347 | How histone modifications influence cellular radiosensitivity: Pharmaceutically targeting epigenetic regulators as a promising avenue to overcome radioresistance. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/41477347 | PubMed |
| 41301681 | Molecular Mechanisms of the Ubiquitin-Specific Proteases (USPs) Family in Biliary Tract Cancer and Targeted Intervention Strategies. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301681 | PubMed |
| 41039553 | Decoding the ubiquitin network: molecular mechanisms and therapeutic vulnerabilities for precision radio-sensitization in cancer. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41039553 | PubMed |
| 40675967 | Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40675967 | PubMed |
| 40580997 | Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. | Oncologist | 2025 | https://conductscience.org/library/papers/40580997 | PubMed |
| 40427072 | Targeting the ZMYM2-ANXA9 Axis with FLT3 Inhibitor G749 Overcomes Oxaliplatin Resistance in Colorectal Cancer. | Biomedicines | 2025 | https://conductscience.org/library/papers/40427072 | PubMed |
Genes36
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33558705
GET https://conductscience.org/api/papers/v1/33558705/cited_by?page=2